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We read with great interest the article by Spec et al. [1]
investigating the immunophenotype of T cells from pa-
tients with Candida spp. sepsis. This is the first observa-
tional study describing the altered immune response of
patients with candidemia. The authors included non-
neutropenic critically ill patients with candidemia and
non-septic controls, and excluded patients with human
immunodeficiency virus infection, who had undergone
solid or bone marrow transplantation or with other
known causes of impaired immune response. The au-
thors hypothesized that their findings may help explain
why patients with fungal sepsis show a high mortality
despite appropriate antifungal therapy.
In our opinion, the observed T-cell exhaustion associated
with candidemia may also contribute to explain the para-
dox of the evidence published recently about invasive fun-
gal infection (IFI) prevention [2]. From our recently
published Cochrane review [3], the use of antifungals in
critically ill patients as untargeted treatment was not asso-
ciated with any survival benefit despite being associated
with a 45 % reduction of IFIs. When prophylactic and
empiric antifungal treatments were investigated in
sub-analyses, a reduction of IFIs was observed only
after prophylactic administration of antifungals. We
hypothesized that studies investigating empiric treatment,
defined as the administration of antifungals in patients
with signs/symptoms of infections at risk for IFIs, in-
cluded patients with a more advanced disease process,
leading to lack of any survival benefit from antifungals.
We now may also speculate that poor survival of patients
despite untargeted antifungal drugs may depend on their
immune status. Patients treated with empiric antifungals
may show an impaired immune response, which may play
a causative role for reduced survival or may represent a
marker of advanced disease process.
Implications for future research may include potential
additional mechanisms of impaired immunological func-
tion to fill the gap between bedside data and pre-clinical
findings.
Abbreviation
IFI, invasive fungal infection
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